ArticleBMC cancer2016
An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.
Donna L Nile et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
39 papers cite it
this papercites it